This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.
Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools
by Zacks Equity Research
Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.
Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases
by Zacks Equity Research
Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
by Zacks Equity Research
Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
by Riya Anand
Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients
by Zacks Equity Research
DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.
Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable
by Zacks Equity Research
Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and its focus on growth strategies.
SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System
by Zacks Equity Research
SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.
Bio Rad (BIO) Grows Internationally on New Product Launches
by Zacks Equity Research
Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.
CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.
Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption
by Zacks Equity Research
Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.
Illumina's (ILMN) New Alliance to Accelerate Genomics in China
by Zacks Equity Research
Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.
Veeva Systems (VEEV) Digital Tools Boost Patient Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) enhancements in digital tools incorporate new ways for seamless communication among healthcare providers and field teams.
Zimmer Biomet's (ZBH) Recovery Slows in Americas Amid Pandemic
by Zacks Equity Research
The third quarter brings greater COVID-related pressure than expected for Zimmer Biomet (ZBH).
CVS Health's (CVS) New Measures to Boost Omnichannel Health
by Zacks Equity Research
CVS Health's (CVS) new measures will support its strategy of making health care more affordable, accessible and convenient for consumers.
LabCorp (LH) to Expand Nonclinical Development With New Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.
Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic
by Zacks Equity Research
Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.
Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings
by Zacks Equity Research
The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
by Zacks Equity Research
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.